BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
246.66
-6.12 (-2.42%)
At close: Jun 20, 2025, 4:00 PM
247.08
+0.42 (0.17%)
After-hours: Jun 20, 2025, 4:11 PM EDT
BeOne Medicines Stock Forecast
Stock Price Forecast
The 7 analysts that cover BeOne Medicines stock have a consensus rating of "Strong Buy" and an average price target of $326.43, which forecasts a 32.34% increase in the stock price over the next year. The lowest target is $311 and the highest is $350.
Price Target: $326.43 (+32.34%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for BeOne Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|
| Strong Buy | 0 | 2 | 2 | 2 |
| Buy | 2 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $312 → $311 | Buy | Maintains | $312 → $311 | +26.08% | May 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $348 → $350 | Strong Buy | Maintains | $348 → $350 | +41.90% | May 8, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $312 | Buy | Reiterates | $312 | +26.49% | Apr 28, 2025 |
| TD Securities | TD Securities | Strong Buy Reiterates $334 | Strong Buy | Reiterates | $334 | +35.41% | Apr 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $311 → $317 | Buy | Maintains | $311 → $317 | +28.52% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
36.93B
from 3.81B
Increased by 869.15%
Revenue Next Year
43.97B
from 36.93B
Increased by 19.07%
EPS This Year
0.35
from -6.12
EPS Next Year
2.58
from 0.35
Increased by 641.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.2B | 48.9B | 56.0B | ||
| Avg | 36.9B | 44.0B | 50.1B | ||
| Low | 35.1B | 37.7B | 43.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 929.8% | 32.5% | 27.4% | ||
| Avg | 869.2% | 19.1% | 14.0% | ||
| Low | 821.3% | 2.2% | -0.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | 3.69 | 5.71 | ||
| Avg | 0.35 | 2.58 | 5.24 | ||
| Low | 0.10 | 1.57 | 4.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 960.5% | 121.3% | ||
| Avg | - | 641.7% | 103.3% | ||
| Low | - | 351.0% | 83.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.